CDEK
← All drugs Report issue

interferon alpha-2b

Trade name: Intron-A

Recombinant proteinapproved

Approved

Jun 4, 1986

Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. Also used to treat hepatitis C, it is no longer recommended due to poor efficacy and adverse side-effects. Subcutaneous injection is the preferred delivery method. — Wikipedia

Clinical trial activity

1,134 trials · 719 clinical orgs · 5 marketing orgs

Phase 1
157
Phase 2
728
Phase 3
318
Phase 4
199

Earliest trial started Oct 25, 1988 (NCT00001228)

Timeline

1980s

  1. Jun 4, 1986

    Merck — Earliest FDA Approval

  2. Jun 4, 1986

    Schering — Marketing Organization

  3. Jun 4, 1986

    Merck — NDA Secondary Org

  4. Jun 4, 1986

    Merck — NDA Organization

  5. Jan 1, 1988

    Earliest Phase 2 Sponsor(trial)

1990s

  1. Jan 1, 1990

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Oct 16, 2002

    Roche — Marketing Organization

  2. Oct 16, 2002

    zr pharma — Marketing Organization

  3. Oct 16, 2002

    zr pharma — NDA Secondary Org

  4. Jun 13, 2008

    Schering-Plough — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 4, 1986

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • alb-ifn
  • albinterferon
  • albinterferon alfa 2b
  • albinterferon alfa-2b
  • albinterferon alfa-2b
  • albinterferon alfa-2b
  • albuferon
  • albuferon
  • albuferon
  • albuferon alpha
  • albuferon-alpha
  • albumin interferon alfa-2b
  • albumin-interferon alpha
  • algeron
  • algeron
  • cepeginterferon alfa 2 b
  • cepeginterferon alfa-2b
  • cepeginterferon alfa-2b
  • human interferon alpha-2b
  • ifnalpha-2b, recombinant
  • inteferon alpha
  • inteferon alpha-2a
  • interf
  • interferon
  • interferon
  • interferon
  • interferon alfa
  • interferon alfa
  • interferon alfa
  • interferon alfa-2a
  • interferon alfa-2a
  • interferon alfa-2a
  • interferon alfa-2a
  • interferon alfa-2a
  • interferon-alfa-2a
  • interferon alfa-2a (genetical recombination)
  • interferon alfa-2a (recombinant)
  • interferon alfa-2a,recombinant
  • interferon alfa-2a, recombinant
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b
  • interferon alfa-2b, recombinant
  • interferon alfa-n1
  • interferon alfa-n1
  • interferon alfa-n1
  • interferon alfa-n1
  • interferon alfa natural
  • interferon alpha
  • interferon alpha
  • interferon alpha
  • interferon-alpha
  • interferon alpha-2
  • interferon alpha-2a
  • interferon alpha 2-b
  • interferon alpha-2b
  • interferon-alpha 2b
  • interferon alpha-2b, recombinant
  • interferon alpha-a
  • interferon alpha-n1 (ins)
  • interferone alpha-2b
  • interferon-α
  • interferon α-2b
  • intron a
  • intron a
  • intron-a
  • intron-a
  • intron-a
  • intron-a
  • intron a hsa-free
  • intron a (interferon)
  • intron a (interferon α2b)
  • intron (interferon α2b)
  • leif a
  • natural alpha interferon
  • novaferon
  • pegasys
  • pegasys
  • pegasys
  • pegasys
  • pegasys
  • peg-ifn alfa-2a
  • peg-ifn alpha-2a
  • peg-ifnalpha-2b
  • peg inf alfa-2b
  • peg inf alpha-2b
  • peginterferon
  • peg-interferon
  • peginterferon alfa
  • peg interferon alfa-2a
  • peg-interferon alfa-2a
  • peg-interferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peginterferon alfa-2a
  • peg-interferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peginterferon alfa-2b
  • peg-interferon alpha-2a
  • peginterferon alpha-2a
  • peginterferon alpha-2b
  • pegintron
  • pegintron
  • pegintron
  • pegintron
  • pegintron
  • peg intron
  • peg-intron
  • peg-intron
  • peg-intron
  • peg-proline-infalpha-2b
  • peg-proline-interferon alfa-2b
  • peg-proline-interferon alpha-2b
  • peg-proline-interferon alpha-2b
  • pegylated human interferon a-2b
  • pegylated interferon alfa -2a
  • pegylated interferon alfa-2a
  • pegylated interferon alfa-2a
  • pegylated interferon alfa-2a
  • pegylated interferon alfa-2b
  • pegylated interferon alfa-2b
  • pegylated interferon-alfa 2b
  • pegylated interferon alpha2a
  • pegylated interferon alpha-2a
  • pegylated interferon alpha-2b
  • pegylated interpheron alpha-2a
  • pegylated-proline-interferon alpha-2b
  • polyethylene glycol-interferon alfa-2a
  • polyethylene glycol-interferon alfa-2b
  • reaferon
  • recombinant human interferon alfa-2a
  • recombinant human interferon alfa-2a
  • recombinant human interferon-alfa-2a
  • recombinant human interferon alpha
  • recombinant interferon a-2b
  • recombinant interferon alpha-2a
  • recombinant interferon alpha-2b
  • rifn-alpha-2a
  • rifn-alpha-2b
  • ro 22-8181
  • ro-228181
  • ro-258310000
  • roferon
  • roferon-a
  • roferon-a
  • roferon-a
  • sch 209702
  • sch-30500
  • sch-30500
  • sch-30500
  • sh-polypeptide-46
  • sylatron
  • viferon
  • viraferon
  • viraferon
  • viraferonpeg
  • viraferon-peg
  • wellferon
  • wellferon

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07249840Phase 1Jun 30, 2026Harvard University
NCT07269470Phase 2May 1, 2026University of Texas at Houston
NCT07199413Phase 1Mar 1, 2026Medical College of Wisconsin
NCT07231276Phase 4Jan 1, 2026Southern Medical University
NCT07282249Phase 3Dec 31, 2025Grand Theravac Life Sciences (Nanjing) Co., Ltd.
NCT07183293N/AOct 31, 2025Xiamen Humanity Hospital
NCT07047885Phase 1Aug 27, 2025PharmaEssentia Corp., University of South Florida
NCT07071636Phase 4Aug 15, 2025Shenzhen Third People's Hospital
NCT07053904Phase 1Apr 21, 2025Efficient Pharma, PharmaEssentia Corp.
NCT06920329N/AApr 20, 2025Xiamen University
NCT06900166Phase 4Apr 1, 2025Fudan University
NCT06827249N/AMar 31, 2025Jinlin University, Soochow University
NCT06290765Phase 4Jan 1, 2025PharmaEssentia Corp.
NCT06468033Phase 3Dec 31, 2024PharmaEssentia Corp.
NCT06734637N/ANov 20, 2024Huazhong University of Science and Technology
NCT06503796Phase 4Aug 31, 2024People's Liberation Army of China
NCT06552429Phase 2Aug 31, 2024Chinese Academy of Medical Sciences, Xiamen Amoytop Biotech Co., Ltd.
NCT07008755N/AJul 31, 2024Zhengzhou University
NCT06430190N/AJul 31, 2024First People's Hospital of Hangzhou
NCT06881056N/AJul 17, 2024Sichuan University
Showing 20 of 1,134 trials
Page 1 / 57

Organizations

Research & Development (719)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RocheFor profit1489151992
National Cancer Institute (NCI)Government1243341994
MerckFor profit1068351996
University of Texas at HoustonAcademic/Hospital434041990
National Institute of Allergy and Infectious Diseases (NIAID)Government373051999
Bristol-Myers SquibbFor profit362941999
Schering-PloughFor profit35251996
VertexFor profit281842004
NovartisFor profit25952000
Johnson and JohnsonFor profit221952009
National Taiwan UniversityAcademic/Hospital222041997
Peking UniversityAcademic/Hospital22642008
PharmaEssentia Corp.For profit211452009
French National Agency for Research on AIDS and Viral HepatitisGovernment202022000
Sun Yat-Sen UniversityAcademic/Hospital202042008
People's Liberation Army of ChinaGovernment181052009
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government171651988
University of PittsburghAcademic/Hospital17941998
Cornell UniversityAcademic/Hospital161331994
National Institutes of Health (NIH)Government16252000
719 organizations
Page 1 / 36

Marketing (7)

OrganizationOrg typeRelationshipDate
MerckFor profitNDA2Jun 4, 1986
MerckFor profitNDAJun 4, 1986
RocheFor profitMKTGOct 16, 2002
ScheringFor profitMKTGJun 4, 1986
Schering-PloughFor profitNDA2Jun 13, 2008
zr pharmaFor profitMKTGOct 16, 2002
zr pharmaFor profitNDA2Oct 16, 2002